Coron Pharmaceutical is expected to increase by 66.39%to 80.59%year -on -year in the first half of 2022

On July 6, Capital State learned that the A-share listed company Coren Pharmaceutical (code: 002422.sz) released the semi-annual report performance forecast. The profit was 820 million to 890 million yuan, and the net profit increased by 66.39%year -on -year to 80.59%. It is expected that the basic earnings per share will be 0.58 to 0.62 yuan.

The company made the above prediction based on the following reasons: the company's holding subsidiary Sichuan Corunbo Tai Biomedical Co., Ltd. (hereinafter referred to as "Coronboita") puts it with independent intellectual property biomolecular tumor project A. ; Dohmellc. (Hereinafter referred to as "MSD") under the regional research, development, manufacturing and commercialization of research, development, manufacturing and commercialization outside China (China includes mainland China, Hong Kong, Macau and Taiwan).

The cooperation between the two parties was promoted normally in accordance with the established plan, and Coronbo Tai received MSD $ 30 million in payment on June 24, 2022 (the actual account amount must be deducted from the tax payment of taxes and banks calculated in accordance with relevant laws. Fee). According to the contract, according to the preliminary calculation of the contract obligations that Correnbo has fulfilled, the above matters will increase the net profit attributable to the parent company about RMB 120 million.

Kelun Pharmaceutical, the company's full name, Sichuan Kelun Pharmaceutical Co., Ltd., was established on May 29, 2002. The current general manager Liu Sichuan. Sterile powder needles (including packaging powder and frozen dried powder needles), tablets, capsules, granules, oral solution, peritoneal dialysis solution and other 25 dosage -type drugs and antibiotic intermediates, raw materials, pharmaceutical packaging materials Such as the development, production and sales of products.

- END -